This chapter examines the current struggles of Dexcom, a leader in continuous glucose monitoring for diabetes care, following a recent stock decline. It highlights key challenges such as a sales team realignment and competitive pressures from rivals like Abbott and Medtronic. Despite these obstacles, the chapter emphasizes Dexcom's significant growth potential and market opportunities within an expanding diabetes device market.
Someone’s gotta make ‘em, and someone’s gotta buy ‘em.
(00:21) Asit Sharma and Mary Long look at earnings from companies on either end of the AI spending spree. They also discuss:
- whether you should fall in love with companies
- AMD’s data center business
- Meta’s “special treatment”
Then, (18:08) Karl Thiel and Ricky Mulvey look at Dexcom, a medical device manufacturer that’s fallen out of favor with Wall Street.
Companies mentioned: AMD, NVDA, META, DXCM, ABT, MDT, ISRG, NVCR
Host: Mary Long
Guests: Asit Sharma, Karl Thiel, Ricky Mulvey
Producer: Ricky Mulvey
Engineers: Dan Boyd, Tim Sparks
Learn more about your ad choices. Visit megaphone.fm/adchoices